DIAGREAT

On February 13, 2026, the globally anticipated 25th WHX Labs Dubai (formerly MEDLAB Middle East) successfully concluded in Dubai. As a leading and influential exhibition for medical laboratory instruments and equipment in the Middle East, the event gathered global industry giants and thousands of exhibitors, attracting professionals from over 180 countries in the laboratory and in vitro diagnostics sector to showcase and exchange cutting-edge medical technologies. As an innovator in China's IVD industry, DIAGREAT made a distinguished appearance at WHX Labs Dubai 2026 with a range of core products. With innovative technologies and high-quality offerings, DIAGREAT impressed the audience and fully presented the strength and brand image of China's in vitro diagnostics industry to the world.

DIAGREAT is committed to building a one-stop IVD solution covering core raw materials, diagnostic reagents, high-precision testing instruments, and nucleic acid synthesis research services. It achieves full-process independent control from upstream raw material supply, reagent R&D and production, to instrument platform development and scientific and technical services.
Among them, the fully automated chemiluminescent solution for therapeutic drug monitoring has attracted wide attention. It integrates automatic sample pretreatment, drug monitoring reagents, and result interpretation services, enabling full-process intelligence and simplifying complex operations. This makes therapeutic drug monitoring faster, more accurate, and easier, providing strong support for precise medication.

DIAGREAT has always taken R&D and innovation as its driving force, with a core R&D team composed of top talents, injecting sustained momentum into technological breakthroughs. At present, its core products have successfully obtained the EU CE certification, as well as strict market access certifications from Italy, Mexico, Venezuela, Ecuador and other countries. These achievements not only serve as authoritative proof of the company’s professionalism in medical technology, but also highlight DIAGREAT’s leading technological position in the global market. In its global layout, DIAGREAT has built a marketing network covering more than 60 countries and regions, laying a solid foundation for business expansion. As a result, its products have won deep recognition from the global market and high praise from the industry.

Future, DIAGREAT will continue to focus on precision medicine, and constantly upgrade its products and services. Meanwhile, the company will vigorously promote innovation in therapeutic drug monitoring, helping to improve the quality of clinical precision medication, and provide global customers with more professional, efficient and precise one-stop IVD solutions.